Tetrasodium pyrophosphate structure
|
Common Name | Tetrasodium pyrophosphate | ||
---|---|---|---|---|
CAS Number | 7722-88-5 | Molecular Weight | 265.902 | |
Density | 2.53 g/mL at 25 °C(lit.) | Boiling Point | 93.8 °C | |
Molecular Formula | Na4O7P2 | Melting Point | 80 °C | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS05, GHS07 |
Signal Word | Danger |
Name | sodium diphosphate |
---|---|
Synonym | More Synonyms |
Density | 2.53 g/mL at 25 °C(lit.) |
---|---|
Boiling Point | 93.8 °C |
Melting Point | 80 °C |
Molecular Formula | Na4O7P2 |
Molecular Weight | 265.902 |
Exact Mass | 265.871002 |
PSA | 155.23000 |
LogP | 0.94120 |
Stability | Stable. Incompatible with strong oxidizing agents. |
Water Solubility | H2O: 0.1 M at 20 °C, clear, colorless |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS05, GHS07 |
---|---|
Signal Word | Danger |
Hazard Statements | H302-H318 |
Precautionary Statements | P280-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi:Irritant |
Risk Phrases | R36/37/38 |
Safety Phrases | S26-S36 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | UX7350000 |
HS Code | 2835399000 |
HS Code | 2835399000 |
---|
The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Drug Des. Devel. Ther. 9 , 1627-52, (2015) Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of hematological and non-hematological malignancies. However, its antitumo... |
|
Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Drug Des. Devel. Ther. 9 , 1555-84, (2015) Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to current therapeutics. Alisertib (ALS, MLN823... |
|
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Drug Des. Devel. Ther. 9 , 425-64, (2015) Ovarian cancer is a leading killer of women, and no cure for advanced ovarian cancer is available. Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, has shown potent anticancer effects, ... |
Sodium pyrophosphate, anhydrous, tech. |
EINECS 231-767-1 |
MFCD00003513 |
Tetrasodium diphosphate |
Tetrasodium pyrophosphate |